




IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : David J. Grainger *et al.*
Serial No. : 09/754,775 Examiner : T.J. Criares
Filed : January 4, 2001 Group Art Unit: 1617
For : PREVENTION AND TREATMENT OF CARDIOVASCULAR PATHOLOGIES WITH TAMOXIFEN ANALOGUES

TERMINAL DISCLAIMER

I hereby certify that this paper is being deposited on April 18, 2005 with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450

Lisa B. Kole

Attorney Name


Signature

35,225

PTO Registration No.
April 18, 2005

Date of Deposit

Commissioner for Patents
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria VA 22313-1450

Sir:

NeoRX Corporation, the owner of the entire interest in U.S. Application Serial No. 09/754,775 filed on January 4, 2001 for "Prevention and Treatment of Cardiovascular Pathologies with Tamoxifen Analogues," which is a continuation of U.S. Application Serial No. 08/973,570, filed December 5, 1997 now U.S. Patent 6,197,789, which is a national stage filing of PCT/US96/10211, filed June 7, 1996, which is a continuation-in-part of U.S. Application Serial No. 08/478,936, filed June 7, 1995, now U.S. Patent 5,595,722; U.S. Application Serial No. 08/477,393, filed June 7, 1995; and U.S. Application Serial No. 08/486,334, filed June 7,

04/21/2005 MAHMED1 00000042 09754775

02 FC:1814

130.00 DP

506733

1995, now U.S. Patent 5,770,609 as evidenced by an assignment to NeoRX Corporation, recorded in the U.S. Patent and Trademark Office on September 8, 1998 at Reel/Frame No. 9434/0042, hereby disclaims the terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term, defined in 35 U.S.C. § 154 to 156 and 173, of commonly owned issued U.S. Patent No. 6,117,911. The owners hereby agree that any patent so granted on the above-identified application shall be enforceable only for and during such period that the above-identified application and granted U.S. Patent No. 6,117,911 are commonly owned. This agreement shall run with any patent granted on the instant application and shall be binding upon the assignees, their successors, or assigns.

The undersigned is attorney of record and has the authority to execute this Terminal Disclaimer on behalf of NeoRX Corporation, and hereby certifies that, to the best of my knowledge and belief, title is in the assignee on whose behalf this terminal disclaimer is being filed.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Pursuant to 37 C.F.R. §1.20 (d), a check is enclosed in the amount of \$130.00.

Should any additional fees be required in connection with this response, the Commissioner is hereby authorized to charge Deposit Account Number 02-4377.

Respectfully submitted,



Lisa B. Kole

Patent Office Reg. No. 35,225
Attorney for Applicant
(212) 408-2628

Baker Botts L.L.P.
30 Rockefeller Plaza
New York NY 10112